hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06376799, orgStudyIdInfo id: 38RC23.0437, secondaryIdInfos id: 2024-A00485-42, type: OTHER, domain: ID RCB, briefTitle: Which Health-care Professional(s) to Talk About Advance Care Planning ?, acronym: QPSPAS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2024-11-02, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: University Hospital, Grenoble, class: OTHER, descriptionModule briefSummary: The goal of this descriptive observational study is to evaluate the preference of French adult patients followed in the context of a oncological disease, regarding the choice of the preferred healthcare professional to discuss advance care planning.To this end, voluntary participants will be asked to indicate their preferences by answering a self-questionnaire available in electronic or paper format., conditionsModule conditions: Advance Care Planning, conditions: Patient Preference, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: Self-questionnaire, outcomesModule primaryOutcomes measure: Determining the healthcare professional preferred by cancer patients to talk about advance care planning, secondaryOutcomes measure: Determining cancer patients' second choice of healthcare professional to talk about advance care planning, secondaryOutcomes measure: Evaluation of patient preferences regarding advance care planning, concerning the form, the moment it should be carried out, whether or not they wish to be accompanied by a relative, and the benefit of systematization, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06376773, orgStudyIdInfo id: 2022KY123, briefTitle: Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping., statusModule overallStatus: COMPLETED, startDateStruct date: 2022-06-01, primaryCompletionDateStruct date: 2023-07-01, completionDateStruct date: 2023-11-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Fujian Medical University, class: OTHER, descriptionModule briefSummary: Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer (GC). Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of GC at the molecular level. This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of gastric cancer.Based on RNA-seq transcriptome, 234 patients were divided into four molecular subtypes: mesenchymal, immunogenic, metabolic, and classic.Our analysis has revealed that, for neoadjuvant therapy in advanced gastric cancer (AGC), the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib, without a concurrent increase in postoperative complications., conditionsModule conditions: Advanced Gastric Cancer, conditions: Neoadjuvant Therapy, conditions: Multi-omics Analysis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 234, type: ACTUAL, armsInterventionsModule interventions name: combination chemotherapy with Apatinib or Camrelizumab, outcomesModule primaryOutcomes measure: overall survival, secondaryOutcomes measure: objective response rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fujian Medical University Union Hospital, city: Fuzhou, state: Fujian, zip: 350000, country: China, geoPoint lat: 26.06139, lon: 119.30611, hasResults: False
protocolSection identificationModule nctId: NCT06376760, orgStudyIdInfo id: KY2024-091-02, briefTitle: Changes in Intravenous Anesthetic Drug Dosage in Insomnia Patients Undergoing Digestive Endoscopy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2027-03-31, completionDateStruct date: 2027-03-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Beijing Tiantan Hospital, class: OTHER, descriptionModule briefSummary: To compare the dosage requirement of intravenous anesthetics during digestive endoscopy between patients with insomnia and those with normal sleep pattern., conditionsModule conditions: Insomnia, conditions: Digestive Endoscopy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 3360, type: ESTIMATED, armsInterventionsModule interventions name: No interventions, it is a observational study, outcomesModule primaryOutcomes measure: The total consumption of intravenous anesthetic drug, secondaryOutcomes measure: The dosage of intravenous anesthetic drug for successful insertion of digestive endoscope, secondaryOutcomes measure: The occurrence of the respiratory and cardiovascular adverse events, secondaryOutcomes measure: The occurrence of the other adverse events, secondaryOutcomes measure: The incidence of intraoperative recall or awareness, secondaryOutcomes measure: The recovery time, secondaryOutcomes measure: Duration of patients' PACU stay, secondaryOutcomes measure: The ease of operation at this level of sedation evaluated by the gastroenterologists, secondaryOutcomes measure: The satisfaction degree of anesthesia effect evaluated by the gastroenterologists, secondaryOutcomes measure: Patients' satisfaction, secondaryOutcomes measure: Patients' willingness, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule locations facility: Beijing Tiantan Hospital, city: Beijing, state: Beijing, zip: 100070, country: China, contacts name: Fang Luo, M.D., role: CONTACT, phone: 13611326978, email: 13611326978@163.com, contacts name: Fang Luo, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06376747, orgStudyIdInfo id: KDAR- PBM 2024, briefTitle: The Influence of Blood Sampling Technique on the Total Amount of Blood Collected for Laboratory Testing Critically Ill Pediatric Patients, acronym: PEDPBM, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-08-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Brno University Hospital, class: OTHER, descriptionModule briefSummary: The aim of this prospective randomized study is to evaluate blood loss caused by laboratory blood draws in patients in the paediatric ICU (Intensive Care Unit) of a tertiary hospital among two groups of patients with established long-term or mid-term intravenous access. In the first group, patients will undergo blood draws using the standard method. In the second group of patients, blood draws will be performed using a closed system., conditionsModule conditions: Iatrogenic Anaemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SCREENING, maskingInfo masking: SINGLE, maskingDescription: Patients will be randomized into two groups: a group with standard blood sampling technique and a group with closed technique blood sampling by using randomizing software., whoMasked: INVESTIGATOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: In line sampling, interventions name: Standard blood sampling technique, outcomesModule primaryOutcomes measure: Average amount of blood collected for laboratory diagnostic purposes, secondaryOutcomes measure: Cumulative amount of blood drawn per day of ICU hospitalization, secondaryOutcomes measure: Absolute amount of blood drawn and blood used for laboratory testing, secondaryOutcomes measure: Trend of haemoglobin decline over time, secondaryOutcomes measure: Incidence of anaemia, secondaryOutcomes measure: Incidence of anaemia up to transfusion trigger, secondaryOutcomes measure: Frequency of blood product transfusions and their quantity, secondaryOutcomes measure: Type and frequency of laboratory tests, secondaryOutcomes measure: Incidence of coagulopathy, secondaryOutcomes measure: Incidence of catheter-related complications, secondaryOutcomes measure: Time to catheter replacement in case of catheter exchange, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 19 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: KDAR - department of pediatrics anesthesia and resuscitation, city: Brno, zip: 62500, country: Czechia, geoPoint lat: 49.19522, lon: 16.60796, hasResults: False
protocolSection identificationModule nctId: NCT06376734, orgStudyIdInfo id: 2024p000528, briefTitle: Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness, acronym: Searchlight, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2029-06-01, completionDateStruct date: 2030-06-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Brigham and Women's Hospital, class: OTHER, collaborators name: National Institutes of Health (NIH), descriptionModule briefSummary: Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits., conditionsModule conditions: Major Depressive Disorder, conditions: Obsessive-Compulsive Disorder, conditions: Schizophrenia, conditions: Generalized Anxiety Disorder, conditions: Mood Disorders, conditions: Psychiatric Disorder, conditions: Mental Disorder, conditions: Depression, Anxiety, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Double-blind, randomized controlled crossover trial. Participants will be stimulated at a random location in the prefrontal cortex, which will be mapped to its underlying brain network to determine which network was stimulated., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, maskingDescription: All participants will receive real open-label TMS, so there will be no conventional masking. However, participants and investigators will be blinded to which network is being stimulated., enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: TMS, outcomesModule primaryOutcomes measure: Clustering of multiple behavioral measures, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06376721, orgStudyIdInfo id: TREC2024-KY016, briefTitle: Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-14, primaryCompletionDateStruct date: 2026-10-31, completionDateStruct date: 2027-10-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Beijing Tongren Hospital, class: OTHER, descriptionModule briefSummary: The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment., conditionsModule conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, conditions: T-lymphoblastic Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Treatment with linperlisib in combination with camrelizumab and pegaspargase for advanced or relapsed/refractory ENKTCL patients, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 43, type: ESTIMATED, armsInterventionsModule interventions name: Linperlisib, interventions name: Camrelizumab, interventions name: Pegaspargase, interventions name: Dexamethasone, outcomesModule primaryOutcomes measure: The best objective response rate（ORR） over 6 treatment cycles, secondaryOutcomes measure: Objective Response Rate（ORR）, secondaryOutcomes measure: Complete Response （CR）, secondaryOutcomes measure: Progression Free Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Disease Control Rate（DCR）, otherOutcomes measure: Drug safety, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Liang Wang, status: RECRUITING, city: Beijing, state: Beijing, country: China, contacts name: Liang Wang, M.D., role: CONTACT, phone: +8615001108693, email: wangliangtrhos@126.com, contacts name: Liang Wang, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06376708, orgStudyIdInfo id: 3-3-13, briefTitle: Comparison Between PEEK With Platelet-rich Fibrin and PEEK Alone in Maxillary Sinus Augmentation, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-01, primaryCompletionDateStruct date: 2023-03-01, completionDateStruct date: 2023-07-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: comparison between the resulted bone during maxillary sinus elevation by PEEK with and without platelet rich fibrin, conditionsModule conditions: Maxillary Sinus, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: use of platelet rich fibrin after maxillary sinus elevation using PEEK, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 24, type: ACTUAL, armsInterventionsModule interventions name: platelet rich fibrin, interventions name: Polyether ether ketone, outcomesModule primaryOutcomes measure: Bone quantity, secondaryOutcomes measure: Bone quality, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Dentistry Cairo University, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06376682, orgStudyIdInfo id: CA-BO-CIP-0060, briefTitle: EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy, acronym: EPIBONE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Quantum Surgical, class: INDUSTRY, descriptionModule briefSummary: Interventional clinical study to obtain performance and safety data of the EPIONE® device when used for bone percutaneous procedures., conditionsModule conditions: Bone Metastases, conditions: Fractures, Bone, conditions: Bone Tumor, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The Epione device is an image-guided robotized device that assists the physician during CT-guided procedures., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 33, type: ESTIMATED, armsInterventionsModule interventions name: CT-guided bone percutaneous procedure, outcomesModule primaryOutcomes measure: Successful instrument insertion with the EPIONE device., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06376669, orgStudyIdInfo id: J2421, secondaryIdInfos id: IRB00427823, type: OTHER, domain: JHM IRB, briefTitle: Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma, acronym: SPARE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2027-06, completionDateStruct date: 2030-08, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, class: OTHER, descriptionModule briefSummary: This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival., conditionsModule conditions: Renal Cell Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Proton Stereotactic Body Radiation therapy (SBRT), outcomesModule primaryOutcomes measure: Change in kidney function after PROTON-BASED SBRT treatment as assessed by serum creatine levels, primaryOutcomes measure: Change in kidney function after PROTON-BASED SBRT treatment as assessed by estimated glomerular rate (eGFR) values, secondaryOutcomes measure: Number of PROTON-BASED SBRT treatment Adverse Events, secondaryOutcomes measure: Local progression of disease after PROTON-BASED SBRT treatment as assessed by size or appearance of lesions, secondaryOutcomes measure: Systemic progression of disease after PROTON-BASED SBRT treatment as assessed by appearance of lesions, secondaryOutcomes measure: Time to locoregional progression, secondaryOutcomes measure: Overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06376656, orgStudyIdInfo id: LRGS/1/2019/SYUC/02/1, briefTitle: Successful Aging and Age-related Decline, acronym: MyAgeWell, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-05-20, primaryCompletionDateStruct date: 2029-05, completionDateStruct date: 2030-05, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Sunway University, class: OTHER, descriptionModule briefSummary: Recent studies have shown promising cognitive and physical interventions aimed at slowing down ageing-related declines in quality of life, but they lack strong ecological validity (brief durations, unrealistic goals, no real-world application) and has yet to show robust evidence that such interventions are stable and suitable in the long-term. The investigators aim to examine whether these interventions can, over four years, significantly slow down the normal rate of ageing-related decline., conditionsModule conditions: Aging, conditions: Elderly, conditions: Cognitive Decline, conditions: Physical Decline, conditions: Intervention Study, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A cohort of older Malaysian adults will be recruited and assigned to one of the groups, either cognitive stimulation, physical activity, combined cognitive stimulation and physical activity, or non-intervention control., primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: Cognitive stimulation, interventions name: Physical activity, outcomesModule primaryOutcomes measure: Changes in cognitive scores, primaryOutcomes measure: Changes in electroencephalogram (EEG), primaryOutcomes measure: Changes in structural magnetic resonance imaging (MRI), primaryOutcomes measure: Cost-benefit analysis of intervention, primaryOutcomes measure: Changes in levels of human salivary lactoferrin, primaryOutcomes measure: Changes in levels of human salivary C-reactive proteins, primaryOutcomes measure: Changes in salivary telomere length, secondaryOutcomes measure: Changes in depression scores, secondaryOutcomes measure: Changes in anxiety scores, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sunway University, status: RECRUITING, city: Petaling Jaya, state: Selangor, zip: 47500, country: Malaysia, contacts name: Michael J Jenkins, PhD, role: CONTACT, phone: +60374918622, phoneExt: 7183, email: michaeljj@sunway.edu.my, geoPoint lat: 3.10726, lon: 101.60671, hasResults: False
protocolSection identificationModule nctId: NCT06376617, orgStudyIdInfo id: MS.24.03.2743, briefTitle: Pattern Of Isolated Fungi From Bronchoalveolar Lavage Among Patients With Bronchial Asthma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-25, primaryCompletionDateStruct date: 2025-04-20, completionDateStruct date: 2025-05-20, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Mansoura University, class: OTHER, descriptionModule briefSummary: This study is to assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma, conditionsModule conditions: Bronchial Asthma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: fibroptic bronchoscopy, outcomesModule primaryOutcomes measure: assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False